Accessibility Toolbar

Bascom Palmer Eye Institute

Continuing Medical Education »

Beach with beach beds

Glaucoma 2.0: Bench to Bedside Program

Program subject to change.

Saturday, January 26, 2013 7:00 a.m. - 4:45 p.m.

  1. 7:00 am Registration and Continental Breakfast
  2. 7:55Welcome and Overview Jeffrey L. Goldberg, MD, PhD and Richard K. Parrish, II, MD
  3. 8:00 am Special Tribute to Francisco E. Fantes, MD*

8:15 - 9:15 Session I - Neuroprotection and Neuroenhancement: A “How To”

  1. 8:15 Neuroprotection: What Is It, Why Do We Need It, and How Do We Measure It? David S. Greenfield, MD, FACS
  2. 8:30 LoGTS: What We Learned About Brimonidine and Clinical Trial Design Jeffrey M. Liebman, MD
  3. 8:45 The Glaucoma Research Network Michael V. Boland, MD, PhD
  4. 9:00 Panel Discussion and Q&A

9:15 - 10:45 Session II – Neuroprotection Evidence from Clinical Trials

  1. 9:15 Rock Inhibitors: Good for IOP and ALSO Good for RGCs? Paul Kaufman, MD
  2. 9:30 Could Hyperbaric Oxygen Help? Magaly A. Rodriguez, MD
  3. 9:45 Cytidine-5-Diphosphocholine Vincenzo M. Parisi, MD
  4. 10:00 Treating Optic Neuropathy with Non-Invasive Alternating Current Stimulation Bernhard A. Sabel, PhD
  5. 10:15 Neuroprotection by Caspase-2 Inhibition for NAION: Phase I Data Leonard A. Levin, MD, PhD
  6. 10:30 Panel Discussion and Q&A
  1. 10:45 pm Break

11:15 - 12:15 Session III - Preventing Synaptic Degeneration

  1. 11:15 C1q: Evidence From Pre-Clinical Models, Approaches to New Therapeutics Ben A. Barres, MD, PhD
  2. 11:30 QRK665: The DEGAS Phase II StudyResults Quan Dong Nyugen, MD, MSc
  3. 11:45 The Theory of Activating Residual Vision After Brain or Retina Damage Bernhard A. Sabel, PhD
  4. 12:00 Panel Discussion and Q&A
  1. 12:15 pm Lunch

1:30 - 2:45 Session IV - Neurotrophic Factors

  1. 1:30 NT-501 CNTF Implant for Glaucoma and NAION: Phase I Data Jeffrey L. Goldberg, MD, PhD
  2. 1:45 GDNF Particles: Human Safety Data for RP; Preclinical Data for Glaucoma Michael J. Young, PhD
  3. 2:00 NGF Eyedrops: Human Safety Data John Dart, MA, FRCS, FRCOphth
  4. 2:15 NGF Eyedrops Case Report Krishna S. Kishor, MD
  5. 2:30 NGF Mimetics Including mimD3 H. Uri Saragovi, PhD
  6. 2:45 Panel Discussion and Q&A

3:00 - 3:45 Session V - Optic Nerve Regeneration

  1. 3:00 BA-210: Overcoming Inhibitors of Regeneration Lisa McKerracher, PhD
  2. 3:15 TNF-alpha Blockade Enhances RGC Survival In Glaucoma Larry Benowitz, PhD
  3. 3:30 TNF-alpha Blockers in Glaucoma Patients: Evidence for Neuroprotection? Louis R. Pasquale, MD
  1. 3:45 m Break

4:00 - 4:45 Session VI - Stem Cell Biology

  1. 4:00 Stem Cell Biology for Trabecular Meshwork Replacement Pratap Challa, MD
  2. 4:15 Stem Cells for Retinal Ganglion Cell Replacement Yvonne Ou, MD
  3. 4:30 Panel Discussion and Q&A
  1. 4:45 pm Adjourn/Cocktail Reception

*No CME offered for this session